


 Europäisches Patentamt
 European Patent Office
 Office européen des brevets

Publication number: **0 260 066 B1**

EUROPEAN PATENT SPECIFICATION

Date of publication of the patent specification:
 09.05.90

Int. Cl.: **C07C 217/54, C07D 295/08, A61K 31/135, A61K 31/40, A61K 43/00, A61K 49/02**

Application number: **87307782.0**

Date of filing: **03.09.87**

Tamoxifen derivatives.

Priority: **11.09.86 GB 8621908**
19.05.87 GB 8711790

Proprietor: **NATIONAL RESEARCH DEVELOPMENT CORPORATION, 101 Newington Causeway, London SE1 6BU(GB)**

Date of publication of application:
 16.03.88 Bulletin 88/11

Inventor: **McCague, Raymond, Flat 4 20 Somers Road, Reigate Surrey RH2 9DZ(GB)**

Publication of the grant of the patent:
 09.05.90 Bulletin 90/19

Representative: **Percy, Richard Keith, Patent Department National Research Development Corporation 101 Newington Causeway, London SE1 6BU(GB)**

Designated Contracting States:
BE CH DE FR GB IT LI NL SE

References cited: (continuation)
 Columbus, Ohio, USA Hunter et al. "The iodotamoxifens: molecular structures and syntheses of estrogens for external imaging of carcinoma" page 525, abstract no. 215 251g
 Chemical Abstracts, vol. 106, no. 1, January 5, 1987, Columbus, Ohio, USA Hunter et al. "An iodine-131 iodotamoxifen: no. carrier added iodination via a diazonium salt" page 430, abstract no. 4 584y

References cited:
 British journal of pharmacology, vol. 71, 1980 K.E. Allen et al. "Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships" pages 83-91
 Chemical Abstracts, vol. 95, no. 15, October 12, 1981, Columbus, Ohio, USA Tonnesen et al.
 "Position-specific radiolodination utilizing an aryltributylstannyl intermediate. Synthesis of 125I-iodotamoxifen" page 628, abstract no. 132 384z
 Chemical Abstracts, vol. 94, no. 7, February 16, 1981, Columbus, Ohio, USA Bloomer et al.
 "Iodine-125-labeled tamoxifen in differentially cytotoxic to cells containing estrogen receptors" page 15, abstract no. 41 160m
 Chemical Abstracts, vol. 98, no. 25, June 20, 1983,

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

ACTORUM AG

EP 0 260 066 B1

ATTORNEY DOCKET NUMBER: 10177-216-999

SERIAL NUMBER: 09/590,002

REFERENCE: B31

BEST AVAILABLE COPY

14 + 1

EUROPEAN PATENT SPECIFICATION

⑭ Date of publication of the patent specification:
09.05.90

⑮ Application number: 87307782.0

⑯ Date of filing: 03.09.87

⑰ Int. Cl.: **C07C 217/54, C07D 295/08,**
A61K 31/135, A61K 31/40,
A61K 43/00, A61K 49/02

⑳ **Tamoxifen derivatives.**

㉑ Priority: 11.09.86 GB 8621908
19.05.87 GB 8711790

㉒ Date of publication of application:
16.03.88 Bulletin 88/11

㉓ Publication of the grant of the patent:
09.05.90 Bulletin 90/19

㉔ Designated Contracting States:
BE CH DE FR GB IT LI NL SE

㉕ References cited:
British journal of pharmacology, vol. 71, 1980 K.E. Allen
et al. "Evidence for the metabolic activation of
non-steroidal antioestrogens: a study of
structure-activity relationships" pages 83-91
Chemical Abstracts, vol. 95, no. 15, October 12, 1981,
Columbus, Ohio, USA Tonnesen et al.
"Position-specific radiolodination utilizing an
aryltritylstannyl intermediate. Synthesis
of 125I-iodotamoxifen" page 628, abstract no. 132 384z
Chemical Abstracts, vol. 94, no. 7, February 16, 1981,
Columbus, Ohio, USA Bloomer et al.
"Iodine-125-labeled tamoxifen in differentially cytotoxic
to cells containing estrogen receptors" page 15,
abstract no. 41 160m
Chemical Abstracts, vol. 98, no. 25, June 20, 1983,

㉖ Proprietor: **NATIONAL RESEARCH DEVELOPMENT
CORPORATION**, 101 Newington Causeway, London
SE1 6BU(GB)

㉗ Inventor: **McCague, Raymond**, Flat 4 20 Somers Road,
Reigate Surrey RH2 9DZ(GB)

㉘ Representative: **Percy, Richard Keith**, Patent
Department National Research Development
Corporation 101 Newington Causeway, London
SE1 6BU(GB)

㉙ References cited: (continuation)
Columbus, Ohio, USA Hunter et al. "The
iodotamoxifens: molecular structures and syntheses of
estrogens for external imaging of carcinoma" page 525,
abstract no. 215 251g
Chemical Abstracts, vol. 106, no. 1, January 5, 1987,
Columbus, Ohio, USA Hunter et al. "An
iodine-131 iodotamoxifen: no. carrier added lodination
via a diazonium salt" page 430, abstract no. 4 584y

The file contains technical information submitted after
the application was filed and not included in this
specification

EP 0 260 066 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description


Background of the invention

1. Field of the invention

This invention relates to derivatives of tamoxifen, their preparation and use in therapy and diagnosis of breast cancer.

2. Description of prior art


Tamoxifen is *Z* (1,2-diphenyl)-1-[4-(2-dimethylaminoethoxy)-phenyl]-1-butene of formula (1)



(1)

Its anti-estrogenic properties have led since 1971 to its clinical use in the treatment of malignant tumours, especially estrogen receptor-positive (hormone-dependent) breast cancer.

Tamoxifen has a relatively low affinity for the estrogen receptor (ER). Attempts have therefore been made to find tamoxifen derivatives having improved ER affinity. Changes have been made in virtually every part of the molecule. One derivative which at first seemed promising was the 4-hydroxy derivative of formula (2)



(2)

in which X = -OH. This compound was shown by *in vitro* tests to be a potent anti-estrogen, but unfortunately proved *in vivo* to be less effective than tamoxifen, owing to rapid glucuronidation of the hydroxyl group followed by excretion.


Several derivatives of tamoxifen are known which have other C-ring 4-position substituents, in which X is methoxy, methyl, fluoro or chloro. These compounds have been evaluated by K.E. Allen *et al.*, British Journal of Pharmacology 71, 83-91 (1980). The methyl, chloro and fluoro derivatives were of particular interest as they are unlikely to be metabolised to the 4-hydroxy derivative and thence glucuronidated. An *in vitro* test of estrogen receptor affinity indicated that tamoxifen was approximately equiactive with its 4-methyl, fluoro- and chloro-derivatives. *In vivo* rat uterine weight tests indicated that these derivatives had lower anti-estrogenic activity than tamoxifen. Other tests indicated that the activity of the 4-methoxy derivative was about the same as tamoxifen.

U.S. Patent 3 288 206 describes a large class of tamoxifen derivatives and its α -methyl and α -propyl analogues, in which the C-ring 4-position is substituted by lower alkyl, lower alkoxy, lower alkylthio or halogen, for use as pharmacological agents having anti estrogenic, hypocholesterolemic and anti-fertility activity; 4-methoxy is preferred. M. Lieberman *et al.*, J. Biol. Chem. 258 4734-4740 (1983) show that C-ring 4-substitution by fluorine or chlorine has no detrimental effect on the ability of tamoxifen to inhibit estradiol-receptor binding, as shown by a test for inhibiting estrogen-induced synthesis of prolactin. In both this reference and also J. Shani *et al.*, J. Med. Chem. 28, 1504-1511 (1985), the C-ring 4-fluoro compound is less anti-estrogenic than tamoxifen in a rat uterine cytosol test.

Summary of the invention

It has now been found that the 4-iodo derivative (formula 2: X = iodo) has greater potency than tamoxifen in relation to estrogen receptor-positive breast cancer. In view of the reports *supra*, that the 4-fluoro and 4-chloro compounds are (at best) of no greater potency than tamoxifen, the present finding is most surprising. Also, the 3-iodo analogues show promise as alternatives to tamoxifen of at least about equal potency.

These tamoxifen derivatives, which are named Ξ 1-[4-(2-dimethylaminoethoxy)phenyl]-1-(3 and 4-iodophenyl)-2-phenyl-1-butene are believed to be new compounds. Analogues thereof in which the dimethylamino group is replaced by other dialkylamino groups or by monoalkylamino groups or a nitrogen-containing saturated heterocyclic ring are also believed to be novel and are potent against ER-positive breast cancer. Accordingly, the present invention provides 3- and 4-iodotamoxifen derivatives which are compounds of formula (3)




(3)

wherein the iodo-substituent is in the 3- or 4-position and the R¹ and R² symbols, which may be the same or different, represent C₁₋₃ alkyl, especially methyl or ethyl, groups or R¹ represents a hydrogen atom and R² a C₁₋₃ alkyl group or R¹ and R² together with the nitrogen atom to which they are attached represent a saturated heterocyclic group, typically having 5 or 6 ring atoms, especially a pyrrolidino, piperidino, 4-methylpiperidino or morpholino group, and their pharmaceutically acceptable acid addition salts.

The invention further includes;

- the 3- and 4-iodotamoxifen derivatives, i.e. the compounds of formula (3) and their pharmaceutically acceptable addition salts for use in treatment of ER-positive breast cancer;
- the 3- and 4-iodotamoxifen derivatives for use in the preparation of a medicament for treatment of ER-positive breast cancer;
- a pharmaceutical composition comprising a 3- or 4-iodotamoxifen derivative in association with a pharmaceutically effective diluent, carrier or excipient;
- a process for the preparation of the 3- and 4-iodotamoxifen derivatives which comprises reacting 1-[4-(2-chloroethoxy)phenyl]-2-phenyl-1-butanone with an organometallic reagent derived from 1,3- or 1,4-diiodo- or -dibromobenzene and capable of addition to a ketone group, in a substantially anhydrous organic solvent, to form a tertiary alcohol, dehydrating the tertiary alcohol to eliminate a molecule of water and thereby form 1-[4-(2-chloroethoxy)phenyl]-1-(3- or 4-iodophenyl)-2-phenyl-1-butene as an isomeric mixture, separating the Ξ isomer and reacting the Ξ isomer with an amine of formula NR¹R², R¹ and R² being defined as above; and
- a process for the preparation of the 3- and 4-iodotamoxifen derivatives which comprises reacting a ketone of formula (4)



(4)

R¹ and R² being defined as above, in one step with an organometallic reagent as defined above, in a substantially anhydrous organic solvent, to form a tertiary alcohol, dehydrating the tertiary alcohol to eliminate a molecule of water and thereby form 1-[3-(2-NR¹R²-substituted ethoxy)phenyl]-1-(3- or 4-iodophenyl)-2-phenyl-1-butene as an isomeric mixture, and separating the Ξ isomer.

The iodotamoxifen derivatives of the invention include *per se* those wherein the iodine atoms comprise radioisotopic iodine atoms. Predominantly useful such atoms are ¹²⁵I for radiotherapy of estrogen recep-


tor-positive breast cancers and ^{131}I and ^{123}I which are gamma-emitters and therefore useful in imaging the tumours. These compounds, for such uses as well as *per se*, are part of the invention.

The radioisotopic iodotamoxifen derivatives can be prepared by a process comprising reacting a compound of formula

5

10

15



(5)

20

wherein R^1 and R^2 are as defined in connection with formula (3) and Y represents a 3- or 4- substituent, whether an atom or a group, capable of being cleaved from its benzene ring (including within this definition a non-radioisotopic iodine atom), with a reagent capable of effecting such cleavage and with a source of radioisotopic iodine (which can be added as molecular iodine or iodide ions according to the cleavage-effecting reagent used and other reaction conditions). Preferably Y is chloro, bromo, iodo or amino.

25

Description of the preferred embodiments

The 4-iodo derivatives are preferred to the 3-iodo. Preferably R^1 and R^2 are both alkyl groups, most preferably methyl, or NR^1R^2 is pyrrolidino.

30

The compounds of formula (3) and their salts are prepared starting from ketones which are known compounds. The preferred reagent for the preparation of the organometallic halobenzene species is *n*-butyllithium. Alternatively the magnesium Grignard reagent can be used. The immediate product of the organometallic reaction is a tertiary alcohol which is then dehydrated to eliminate a molecule of water and thereby provide the ethylenic double bond required. The dehydration is preferably carried out by heating the alcohol in a strong acid such as concentrated hydrochloric acid. A mixture of isomers is produced, of which the desired one is that in which the ethyl group and the (2-aminoethoxy)phenyl group are trans. The *Z/E* nomenclature designates this as *Z* for tamoxifen itself and *E* for the iodo derivatives.

35

In one embodiment of the invention, the starting ketone already contains the (2-aminoethoxy)phenyl group and therefore the reaction can be carried out in one step (since the tertiary alcohol need not be isolated). The isomer separation is then carried out on the end product.

40

Alternatively, the starting ketone contains the (2-chloroethoxy)phenyl group. The dehydration to the olefin yields the (2-chloroethoxy)phenyl intermediate. The isomers can be separated by crystallisation, which is very convenient, and the desired *E* isomer appropriately aminated by reaction with the alkylamine or heterocyclic amine required. The amination can be carried out in any manner known in the synthesis of tamoxifen, for example heating the chloroethoxy intermediate with the amine in a sealed vessel.

45

The acid addition salts can be prepared in any manner analogous to those of tamoxifen, at any appropriate stage of the overall synthesis after formation of the tertiary alcohol. Usually they will be prepared as the final stage. Examples of such salts are the hydrochloride, sulphate, phosphate, acetate and citrate. In the "direct" method of preparation of the iodo or bromotamoxifen derivatives, an acid addition salt is formed under the acidic dehydration conditions used. This will ordinarily be neutralised with, say, sodium hydroxide. The isomers can then be separated either as the free bases or, after adding a approximately stoichiometric proportion of acid, as acid addition salts.

50

For pharmaceutical formulation, the iodotamoxifen derivatives can be formulated in the same or a similar way to tamoxifen and administered similarly and in about the same dose. Preferably they are formulated as tablets.

55

The iodotamoxifen derivatives include those wherein the iodine atoms in some or all of the molecules of a given sample have a radioisotopic (a radioactive or "hot") iodine atom. Predominantly useful such atoms are ^{125}I which emits low energy electrons having a short, sub-cellular range and ^{131}I and ^{123}I which emit gamma rays. The ^{125}I isotopic iodine is useful in the therapy of tumour cells containing oestrogen receptors, in the same manner as has already been reported for another ^{125}I tamoxifen derivative in which the iodine atom is attached to the same benzene ring as the 2-dimethylaminoethoxy group, in the *ortho* position thereto, see W.D. Bloomer *et al.*, *Int. J. Radiat. Biol.*, **38**, 197-202 (1980). The ^{123}I and ^{131}I isotopes, of which ^{131}I is preferred, are gamma emitters and therefore usable for imaging of oestrogen receptor-carrying tumour cells. The use of all these three isotopes in another iodotamoxifen, namely that in which the iodine atom is present in the "diagonally opposite" position to that of formula (3), that is to say is *para*

60


65

in the benzene ring attached to the carbon atom to which the ethyl group is also attached, is suggested by D.H. Hunter *et al.*, Can. J. Chem. 61, 421-426 (1983). The content of radioisotopic iodine in the iodotamoxifen formulation should be adjusted to conform to conventional radiotherapy and imaging practice.

The commonly used radioisotopes of iodine have a short half-life, for ^{131}I 8 days, for ^{125}I 60 days, and for ^{123}I 13 hours. It is therefore necessary to prepare the radioisotopic compounds of the invention only shortly before the expected time of use. One suitable method of preparation, referred to above, starts from the corresponding compound substituted by non-radioactive ("cold") iodo or by some other atom or group, for example chloro, bromo or amino, capable of undergoing a reaction in which the cold iodo or other atom or group is pulled off or cleaved from the benzene ring of the tamoxifen molecule.

In one aspect the starting compound is the "cold" iodotamoxifen, which is reacted with a copper (I) or (II) salt and an appropriate source of "hot" (radioisotopic) iodide such as sodium iodide. This is a modified version of the Rosenmund-von Braun reaction in which an aryl iodide is convertible to the aryl cyanide by the action of copper (I) cyanide. Since this method does not give an iodotamoxifen product having a high proportion of its iodine atoms in radioisotopic form, it is not well suited to the production of iodotamoxifen for imaging purposes.

Another embodiment comprises reacting the starting compound containing the "cold" atom or group with an alkyllithium and "hot" molecular iodine, in an inert atmosphere. The reaction mechanism is illustrated below using bromine as the cleavable atom and t-butyl lithium as the reagent which effects the cleavage. Ar denotes the residue of the tamoxifen molecule.



Other alkyllithium reagents could be used in place of t-butyl lithium. The reaction takes place in a non-oxidising atmosphere in order to avoid production of a hydroxytamoxifen and a reducing atmosphere such as would react with molecular iodine is also to be avoided. An inert atmosphere is therefore the most suitable.

The reaction temperature can be any appropriate to the reaction equilibrium but is usually in the range of -80 to $+20^\circ\text{C}$. A solvent is normally required and can be any appropriate to the temperature. Tetrahydrofuran is preferred at low temperatures. The iodine should be added in stoichiometric excess for the reaction. Preferably the radioisotopic iodine is added portionwise, less than the stoichiometric amount being added initially, whereby up to half of the radioisotopic I_2 molecules added will become incorporated in the tamoxifen molecule. Addition of the remainder of the iodine, to a stoichiometric excess in total, as "cold" iodine will ensure that there is no avoidable wastage of the radioisotope. Of course, some of it (theoretically a half) will be wasted as iodide ions, which, however, can be recovered by methods known to those skilled in the radioisotope art.

It will be seen that the 4-bromotamoxifen derivatives of formula (5) are useful as intermediates in the preparation of radioisotopic 4-iodotamoxifen derivatives. When a 4-chlorotamoxifen is used as the starting compound, it can be prepared analogously to the 4-bromotamoxifen derivatives described herein. The amino group of the 4-amino analogue can be cleaved and iodine substituted by the action of hypophosphorous acid and radiolabelled sodium iodide.

Another method proceeds via a tributyltin intermediate, which can be stored and then converted to the iodotamoxifen immediately before use. This intermediate can be prepared by reacting the 4-bromo- or iodotamoxifen derivative with n-butyllithium (as described above) and then with tributyl tin chloride. This method has been described by W.D. Bloomer *et al.*, *supra*.

Other methods of introducing a radioactive iodine atom will be found in R.H. SeEVERS and R.E. COUNSEL, Chem. Rev. 82, 575-590 (1982) and such methods are usable *mutatis mutandis* in the context of the present invention.

The following Examples illustrate the invention. Examples 1-6 illustrate preparation of iodo and bromotamoxifen derivatives. "Ether" means diethyl ether. Examples 7 and 8 indicate antiestrogenic effects of the iodotamoxifen derivatives and Example 9 a pharmaceutical composition. Examples 10 and 11 illustrate preparation of radioisotopic iodotamoxifen derivatives.

EXAMPLE 1

Preparation of E 1-[4-(2-dimethylaminoethoxy)phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene ("4-iodotamoxifen")

5 A stirred solution of 1,4-diiodobenzene (4.21 g, 12.7 mmol) in dry tetrahydrofuran (20 ml) was cooled under nitrogen by a dry ice-acetone bath. *n*-Butyllithium (8.5 ml of a 1.55 M solution in hexane, 12.7 mmol) was added. After 5 minutes, a solution of 1-[4-(2-dimethylaminoethoxy)phenyl]-2-phenyl-1-butanone (2.0 g, 6.4 mmol) was added and the mixture allowed to warm to room temperature. After 15 hours, the mixture
10 was poured into water (60 ml) and extracted with ether (2 x 50 ml). The ether extracts were concentrated and the residual oil dissolved in ethanol (20 ml). Concentrated hydrochloric acid (10 ml) was added and the mixture heated under reflux for 4 hours, then cooled, and poured into water (100 ml). The solution was basified with aqueous sodium hydroxide (3 M) and extracted with ether (100 ml). The ether extract was dried with sodium sulphate, concentrated, and the residue applied to a column of silica (Merck 15111, 80 g). Elution with 1:1 light petroleum (b.p. 40-60°C) - ether containing an increasing proportion of triethyl-
15 amine gave after a forerun of tamoxifen which was discarded, at 5% triethylamine, a mixture of 4-iodotamoxifen and its *Z* isomer:-

- | | | |
|----|---|----------------------|
| 20 | (i) 241 mg consisting of 3:1 <u>trans</u> (<u>E</u>): <u>cis</u> (<u>Z</u>) isomers | |
| | (ii) 363 mg consisting of 1:1 <u>trans</u> (<u>E</u>): <u>cis</u> (<u>Z</u>) isomers | as determined by NMR |
| 25 | (iii) 406.5 mg consisting of 1:2 <u>trans</u> (<u>E</u>): <u>cis</u> (<u>Z</u>) isomers | |

30 The total yield of products was 1.01 g (32%).
Recrystallisation of band (i) above gave a sample of the title compound, pure trans (E) isomer, m.p. 112-114°C (from light petroleum, b.p. 40-60°C). Found C, 62.88; H, 5.72; N, 2.79; I, 25.30%. C₂₆H₂₈INO requires C, 62.78; H, 5.67; N, 2.82; I, 25.51% NMR: δ_H (CDCl₃, 250 MHz) 0.91 (3 H, t, \downarrow 7.4 Hz, CH₃CH₂), 2.28 (6 H, s, NMe₂), 2.43 (2 H, q, \downarrow 7.4 Hz, CH₃CH₂), 2.64 (2 H, t, \downarrow 5.8 Hz, OCH₂CH₂N), 3.92 (2 H, t, \downarrow 5.8 Hz, OCH₂CH₂N), 6.55 (2 H, d, \downarrow 8.8 Hz, H-3,5 of C-C₆H₄-O), 6.73 (2 H, d, \downarrow 8.8 Hz, H-2,6 of C-C₆H₄-O), 6.98 (2 H, d, \downarrow 8.3 Hz, H-2,6 of C-C₆H₄-I), 7.04-7.22 (5 H, m, Ph), 7.66 (2 H, d, \downarrow 8.3 Hz, H-3,5 of C-C₆H₄-I); mass spectrum *m/z* 497 (M⁺, 36%), 380(3), 252(13), 72(100), 58(100).
The cis (Z) isomer gave δ_H (CDCl₃, 60 MHz) inter alia 2.32 (6 H, s, NMe₂), 4.07 (2 H, t, \downarrow 6 Hz, OCH₂CH₂N).
40

EXAMPLE 2

Preparation of E 1-[4-(2-dimethylaminoethoxy)phenyl]-2-(4-bromophenyl)-2-phenyl-1-butene ("4-bromotamoxifen")

45 A stirred solution of 1,4-dibromobenzene (6.88 g, 29.15 mmol) in dry tetrahydrofuran (30 ml) was cooled under nitrogen by a dry ice-acetone bath and *n*-butyllithium (15.1 ml of a 1.55 M solution in hexane; 24 mmol) added over 2 minutes. A precipitate formed. After 10 minutes, a solution of 1-[4-(2-dimethylaminoethoxy)phenyl]-2-phenyl-1-butanone (6.09 g, 19.43 mmol) in tetrahydrofuran (15 ml) was added and the mixture allowed to warm to room temperature.
50 After 16 hours, the mixture was worked up as described above for 4-iodotamoxifen to give crude tertiary alcohol as a solid, which was dissolved in ethanol (100 ml). Concentrated hydrochloric acid (60 ml) was added and the mixture heated up under reflux for 20 hours. Work up was as described above for 4-iodotamoxifen. The crude product was dissolved in hot light petroleum (b.p. 80-100°C) (40 ml). Cooling
55 gave crystals of the title compound, i.e., the trans (E) isomer, (2.78 g, 32% yield). The mother liquors were applied to a column of silica (60 g). Elution with 20:20:1 light petroleum (b.p. 40-60°C) -ether-triethylamine gave
60

- (i) 4.36 g oil consisting of 2.5:1 Z:E isomers
(ii) 0.58 g oil consisting of 4:1 Z:E isomers

65 The total yield was 7.72 g, 88%. The proportion of isomers in the crude product was estimated as 1.2:1. Recrystallisation of (i) gave further trans (E) isomer, 0.19 g, then cis (Z) isomer, 1.10 g.

In a repeat of this reaction, but using a milder dehydration procedure (25 ml conc. HCl, 200 ml ethanol, reflux 30 minutes) the ratio of isomers in the crude product was improved to 1.6:1 but the yield was lower, 72% (35% yield of *trans* (E) isomer isolated following recrystallisation).

The *trans* (E) isomer, 4-bromotamoxifen, had m.p. 114-116°C (from light petroleum, b.p. 80-100°C). Found C, 69.44; H, 6.29; N, 2.92; Br, 17.88. C₂₆H₂₈BrNO requires C, 69.32; H, 6.26; N, 3.11; Br, 17.74%; NMR: δ _H(CDCl₃, 250 MHz) 0.91 (3 H, t, \downarrow 7.4 Hz, CH₃CH₂), 2.28 (6 H, s, NMe₂), 2.44 (2 H, q, \downarrow 7.4 Hz, CH₃CH₂), 2.64 (2 H, t, \downarrow 5.7 Hz, OCH₂CH₂N), 3.92 (2 H, t, \downarrow 5.7 Hz, OCH₂CH₂N), 6.56 (2 H, d, \downarrow 8.8 Hz, ArH *ortho* to OR), 6.73 (2 H, d, \downarrow 8.8 Hz, ArH *meta* to OR), 7.08-7.26 (7 H, m, ArH), 7.46 (2 H, d, \downarrow 8.3 Hz, ArH *ortho* to Br).

The *cis* (Z) isomer had m.p. 77-78°C (from light petroleum, b.p. 80-100°C). Found C, 69.49; H, 6.31; N, 3.05; Br, 17.70. C₂₆H₂₈BrNO requires C, 69.33; H, 6.27; N, 3.11; Br, 17.74%; δ _H(CDCl₃, 60 MHz), 0.90 (3 H, t, \downarrow 7 Hz, CH₃CH₂), 2.31 (6 H, s, NMe₂), 2.48 H, q, \downarrow 7 Hz, CH₃CH₂), 2.71 (2 H, t, \downarrow 6 Hz, OCH₂CH₂NMe₂), 4.06 (2 H, t, \downarrow 6 Hz, OCH₂CH₂NMe₂), 6.62 (2 H, d, \downarrow 9 Hz, ArH *ortho* to OR), 6.9-7.3 (11 H, m, ArH).

EXAMPLE 3

Preparation of 4-iodotamoxifen via the (2-chloroethoxy)phenyl intermediate

1-[4-(2-chloroethoxy)phenyl]-2-phenyl-1-butanone has been prepared by R. McCague, J. Chem. Research, 1986, (S), 58-9; (M), 771-93, by Friedel-Crafts condensation of 2-phenylbutanoic acid and (2-chloroethoxy)benzene. 2-Phenylbutanoic acid is commercially available. (2-Chloroethoxy)benzene is obtainable by alkylation of phenol with 1,2-dichloroethane or by reaction of 2-phenoxyethanol with thionyl chloride.

A stirred solution of 1,4-diiodobenzene (21.8 g, 66 mmol) in dry tetrahydrofuran (100 ml) under nitrogen was cooled to ca. -75°C and *n*-butyllithium (41.2 ml of a 1.6 M solution in hexane, 66 mmol) introduced over 5 minutes. After 10 minutes, a solution of 1-[4-(2-chloroethoxy)phenyl]-2-phenyl-1-butanone (20.0 g, 66 mmol) in dry tetrahydrofuran (40 ml) was added and the mixture allowed to warm to room temperature. After 20 hours, the mixture was partitioned between water (200 ml) and ether (200 ml). The ether solution was concentrated and the residual oil dissolved in ethanol (300 ml). Concentrated hydrochloric acid (100 ml) was added, the mixture heated under reflux for 4 hours, then cooled and poured into water (300 ml). The products were extracted with ether (2 x 150 ml), the combined extracts washed with water (200 ml), dried with sodium sulphate and concentrated to give a brown oil which was dissolved in ethanol (200 ml). Crystals of mainly 2-[4-(2-chloroethoxy)phenyl]-2-(4-iodophenyl)-2-phenyl-1-butene, i.e., the desired *trans* (E) isomer, of the (2-chloroethoxy)phenyl intermediate, were deposited, recrystallisation of which gave the pure isomer (12.92 g, 40%), m.p. 96-97°C. Concentration of the original mother liquors gave the *cis* (Z) isomer (7.03 g, 22%), m.p. 110-112°C.

Analysis of the crude oil by proton n.m.r. spectroscopy showed that it contained a 1.5:1 mixture of *trans* (E) and *cis* (Z) isomers.

A solution of E-1-[4-(2-chloroethoxy)phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene (3.05 g) in 33% diethylamine in ethanol (60 ml) was boiled under reflux for 20 hours. The mixture was concentrated, a procedure made necessary only because of escape of the gaseous dimethylamine under these conditions, further 33% dimethylamine solution (60 ml) was added and reflux was continued for a further 20 hours. The mixture was again concentrated and the residue partitioned between ether (50 ml) and aqueous sodium hydroxide (1 M; 050 ml). The ether solution was concentrated and the residue applied to a column of silica gel (Merck 15111, 40 g). Column chromatography was needed to remove a small amount of unreacted starting material from the product which could not be removed by recrystallisation. This problem and the concentration step during addition of dimethylamine could have been overcome by carrying out the reaction in a sealed bomb. Elution with 5% methylamine in 1:1 ether-light petroleum (b.p. 40-60°C) gave 4-iodotamoxifen, which was further purified by recrystallisation from light petroleum (b.p. 40-60°C) (2.60 g, 84% yield), identical to that of Example 1.

EXAMPLE 4

Preparation of E-1-[4-(2-Diethylaminoethoxy)phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene

The method of Example 3 was used, replacing the dimethylamine addition by a single portion of 1:1 diethylamine-ethanol (v/v) and refluxing for 2 days. 1.069 g of the (2-chloroethoxy)phenyl compound gave 1.03 g (93%) of the title compound, m.p. 58-59°C. Found: C, 64.10; H, 6.21; N, 2.63; I, 24.12. C₂₈H₃₂INO requires C, 64.00; H, 6.14; N, 2.67; I, 24.15%.

EXAMPLE 5Preparation of E-1-[4-(2-(N-pyrrolidino)ethoxy)phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene

- 5 The chloroethoxy compound (1.748 g) prepared as in Example 3 and pyrrolidine (10 ml) in ethanol (30 ml) were heated under reflux for 2 hours. The mixture was then concentrated and partitioned between ether (30 ml) and aqueous sodium hydroxide (1 M; 30 ml). The ether solution was concentrated and the title compound recrystallised from light petroleum (b.p. 80-100°C), yield 1.72 g, (92%), m.p. 108-109°C. Found: C,64.28; H,5.83; N,2.64; I,24.06. $C_{26}H_{30}INO$ requires C,64.25; H,5.78; N,2.68; I,24.24%. (Owing to greater reactivity of pyrrolidine than dimethylamine or diethylamine, all the starting material was consumed rapidly and chromatography was not required).

EXAMPLE 6

- 15 Preparation of E 1-[4-(2-dimethylaminoethoxy)phenyl]-2-(3-iodophenyl)-2-phenyl-1-butene ("3-iodotamoxifen")

- A stirred solution of 1,3-diiodobenzene (5.45 g, 16.5 mmol) in dry tetrahydrofuran (25 ml) at -78°C under nitrogen was treated with a solution of *n*-butyl lithium in hexane (1.6 M; 10.3 ml, 16.5 mmol). After 5 min, a solution of 1-[4-(2-chloroethoxy)-phenyl]-2-phenyl-1-butene (5.0 g, 16.5 mmol) in dry tetrahydrofuran (15 ml) was added and the mixture allowed to warm to room temperature. After 20 h, the mixture was poured into water (100 ml) and the product extracted with ether (2 x 50 ml). The extracts were concentrated under vacuum and the residue dissolved in ethanol (80 ml). Concentrated hydrochloric acid (30 ml) was added and the mixture heated under reflux. After 4 h, the mixture was cooled and partitioned between water (100 ml) and ether (2 x 60 ml). The ether layers were dried with sodium sulphate, concentrated, and the residue chromatographed on silica gel (Merck 15111, 60 g). Elution with 1:20 dichloromethane and light petroleum (b.p. 60-80°C) gave 1-[4-(chloroethoxy)phenyl]-1-(3-iodophenyl)-2-phenyl-1-butene as a ca. 1.5 : 1 mixture of *E* (*trans*) and *Z* (*cis*) isomers (determined by n.m.r. spectroscopy) and as an oil (6.46 g, 80% yield). This mixture (3.63 g) was dissolved in a solution of methylamine (30% w/v) in ethanol, and the resulting solution heated in a sealed vessel at 100°C for 4 h, then cooled and concentrated to dryness. The residue was partitioned between aqueous sodium hydroxide (100 ml) and ether (100 ml). The ether solution was washed with water (50 ml), dried with sodium sulphate and the residual oil dissolved in cyclohexane (10 ml). Eventually 3-iodotamoxifen crystallised (1.51 g, 41%), m.p. 55-57°C. NMR: δ H (CDCl₃, 250 MHz) 0.91 (3H, t, \downarrow 7.4 Hz, CH₃CH₂), 2.29 (3H, s, NMe₂), 2.43 (2H, q, \downarrow 7.4 Hz, CH₂CH₂), 2.65 (2H, t, \downarrow 5.8 Hz, OCH₂CH₂N), 3.93 (2H, t, \downarrow 5.8 Hz, OCH₂CH₂N), 6.57 (2H, d, \downarrow 8.8 Hz, ArH *ortho* to side chain), 6.74 (2H, d, \downarrow 8.8 Hz, ArH *meta* to side chain), 7.05-7.26 (7H, m, ArH), 7.58-7.63 (2H, m, ArH *ortho* to I).

EXAMPLE 7

- 40 Relative binding affinities (RBA) of 4-iodotamoxifen and also of tamoxifen and 4-bromo and 4-hydroxytamoxifen for comparison were determined by a rat uterine cytosol test, as follows. Immature rat uterine cytosol was incubated at 18°C for 30 minutes with 5×10^{-9} M (³H)estradiol in the absence and presence of increasing amounts (10^{-9} - 10^{-5} M) of the test compound or unlabelled estradiol (control). Unbound compounds were then removed with dextran-coated charcoal, and the amounts of estrogen receptor-bound (³H) estradiol were measured. The relative concentrations of estradiol and test compound required to achieve 50% inhibition of (³H)estradiol binding are the RBA: $RBA = ([Isol](estradiol)/[Isol](test compound)) \times 100$.

- 50 A whole cell assay was then performed using the MCF-7 human breast cancer cell line obtained from the Michigan Cancer Foundation, Detroit, USA. MCF-7 cells were maintained at 37°C in monolayer culture in closed T-25 dishes in minimal essential medium (MEM) supplemented with L-glutamine (0.6 mg/ml), gentamycin (40 micrograms/ml), penicillin (100 U/ml) streptomycin (100 micrograms/ml) and 10% inactivated fetal calf serum (inactivated for 1 hour at 56°C). The MCF-7 cells were incubated at 37°C for 50 minutes with 10^{-9} M (³H)estradiol in the absence or presence of increasing amounts (10^{-10} - 10^{-5} M) of the test compound or unlabelled estradiol (control). Bound compounds were then extracted with ethanol, and the amounts of estrogen receptor bound (³H) estradiol were measured. The RBA values were calculated as for the rat uterine cytosol.

The RBA values are shown below in Table 1.

	Rat uterine cytosol	MCF-7 whole cells
Tamoxifen	0.5-1.0	0.06
4-Hydroxytamoxifen	100	2.9
4-Iodotamoxifen	30	0.05
4-Bromotamoxifen	3	0.02

The higher the values in the rat uterine cytosol test the greater the antiestrogenic effect. In the whole cell test, on the other hand, the estrogen receptors are localised in the cell nucleus and therefore bound to DNA. In the whole cell test, a low value indicating poor binding to cell nucleus ER and consequently low estrogenicity, can be considered favourable.

EXAMPLE 8

MCF-7 cells were grown as described in Example 7 and incubated at 37°C for 24 hours with the test compound at three different concentrations. The test compounds according to the invention used were 3- and 4- iodotamoxifen and the analogues of 4-iodotamoxifen in which the dimethylamino group is replaced by diethylamino and pyrrolidino (Examples 4 and 5 respectively). For comparison Z isomers of two of these compounds, 4-bromotamoxifen and tamoxifen itself were tested. Figures in Table 2 below give the percentage cell growth compared with a "blank" sample, and standard deviations obtained from figures for four separate samples of culture. Values greater than 100 indicate a growth stimulating (estrogenic) effect.

TABLE 2

Test Compound (tamoxifen and derivatives and analogues thereof)	MCF-7 Cell Growth, % of Control		
	Concentration of test compound		
	10 ⁻⁸ M	10 ⁻⁷ M	10 ⁻⁶ M
4-Iodotamoxifen	115 ± 6	42 ± 6	26 ± 2
Z Isomer of 4-Iodotamoxifen (comparative)	99 ± 13	126 ± 6	120 ± 3
3-Iodotamoxifen	100 ± 8	68 ± 2	27 ± 5
N,N-diethylamino analogue of 4-Iodotamoxifen	101 ± 7	35 ± 5	23 ± 2
Pyrrolidino analogue of 4-Iodotamoxifen	84 ± 5	27 ± 3	20 ± 2
4-Bromotamoxifen (comparative)	130 ± 10	101 ± 8	63 ± 8
Z Isomer of 4-bromotamoxifen (comparative)	110 ± 3	163 ± 4	174 ± 8
TAMOXIFEN (comparative)*	(not tested)	52 ± 1	30 ± 1

*Note: These figures for tamoxifen have subsequently been corrected to 119 ± 6; 100 ± 6 and 70 ± 8, by a document placed in the official file.

It will be appreciated from Table 2 that 10⁻⁸M was too low a concentration to differentiate the test compounds adequately and that 10⁻⁶M was more realistic. The results indicate that the 4-iodo pyrrolidino derivative is particularly active, followed by the N,N-diethylamino derivative and the 4-iodo compound itself.

EXAMPLE 9

Following the procedure of Example 3 of US patent 4,536,516 (ICI), 50 parts of 4-iodotamoxifen, 42 parts of maize starch and 7 parts of alginic acid are intimately mixed and granulated using 10% maize starch paste as the granulating agent. The granules are dried at a temperature not exceeding 50°C, and then mixed with 1 part of magnesium stearate and compressed into tablets each weighing 50 mg. There are thus obtained tablets suitable for oral administration for therapeutic purposes.

EXAMPLE 10Preparation of 4-iodotamoxifen from 4-bromotamoxifen

5 This Example shows that 4-bromotamoxifen is readily convertible into 4-iodotamoxifen. The Example was carried out using ordinary ("cold", non-radioisotopic) molecular iodine, for reasons of laboratory safety but could obviously be repeated substituting a radioisotopic iodine for ordinary iodine.

10 To a stirred solution of E-1-[4-[2-dimethylamino)ethoxy]-1-(4-bromophenyl)-2-phenyl-1-butene (146.5 mg, 0.325 mmol) in tetrahydrofuran (1 ml) cooled to ca. -75°C under an atmosphere of nitrogen was added a solution of tert-butyllithium in pentane (1.8M; 0.27ml, 0.488 mmol). After 5 min, a solution of iodine (101.5 mg, 0.40 mmol) in tetrahydrofuran (1 ml) was added and the mixture allowed to warm to room temperature, then diluted with water (5 ml) and extracted with ether (2 x 5 ml). The ether solution was dried with sodium sulphate and concentrated. The residual oil was virtually entirely 4-iodotamoxifen by NMR. The product was recrystallized from light petroleum, b.p. 60-80°C. Yield 108.6 mg, 67%, m.p. 110°C (previously recorded m.p. 112-114°C).


15 Note that half of the iodine is lost as iodide by the reaction $Ar + I_2 + ArI + I^-$ (where Ar represents the residue of the tamoxifen molecule). In a radiolabelled synthesis it would be advisable to add first a portion less than an equivalent and I_2 of radioisotopic iodine, then "cold" iodine to bring the reaction to completion.

EXAMPLE 11Preparation of ^{125}I 4-iodotamoxifen from non-radioisotopic 4-iodotamoxifen

25 8mg of "cold" 4-iodotamoxifen were dissolved in 1:1 ethanol-ethyl acetate. To this solution was added 25 μ l of a solution prepared by dissolution of 12mg copper (II) sulphate in 500 μ l methanol, and also 5 μ l of a solution of sodium iodide-125 (ca.100 μ l Ci) in dilute sodium hydroxide. This mixture was heated for 1 h at 106-107°C in a 2ml sealed vessel ("Reacti-vial"). Thin layer chromatography on silica gel (eluant 1:1 v/v ethanol-ethyl acetate or 4:4:1 v/v/v petroleum ether - diethyl ether-triethylamine) indicated more than 99% exchange labelling.

Claims

35 1. 3- and 4-iodotamoxifen derivatives which are compounds of formula (3)



(3)

50 wherein the iodo substituent is present in the 3- or 4-position and R^1 and R^2 , which may be the same or different, represent C_{1-3} alkyl groups or R^1 represents a hydrogen atom and R^2 a C_{1-3} alkyl group or R^1 and R^2 together with the nitrogen atom to which they are attached represent a saturated heterocyclic group and their pharmaceutically acceptable acid addition salts.

55 2. Iodotamoxifen derivatives according to Claim 1 wherein R^1 and R^2 represent methyl groups or R^1 and R^2 together with the said nitrogen atom represent a pyrrolidino group.

3. Iodotamoxifen derivatives according to Claim 2 wherein the iodo substituent is in the 4- position.

4. Iodotamoxifen derivatives according to Claim 1, 2 or 3 wherein the iodine atom is non-radioisotopic.

5. Iodotamoxifen derivatives according to Claim 1, 2, 3 or 4 for use in treatment of estrogen receptor-positive breast cancer.

6. Iodotamoxifen derivatives according to Claim 1, 2, 3 or 4 for use in the preparation of a medicament for treatment of estrogen receptor-positive breast cancer.


60 7. A pharmaceutical composition comprising an iodotamoxifen derivative according to Claim 1, 2, 3 or 4, in association with a pharmaceutically effective diluent, carrier or excipient.

8. Iodotamoxifen derivatives according to Claim 1, 2 or 3 wherein the iodine atom comprises ^{125}I .

65 9. Radioisotopic iodotamoxifen derivatives according to Claim 1, 2, 3 or 8 for use in the preparation of a medicament for treatment of estrogen receptor-positive breast cancer.

10. Radioisotopic iodotamoxifen derivatives according to Claim 1, 2 or 3, wherein the iodine atom comprises ^{123}I or ^{131}I , for use in preparation of a formulation for gamma-ray photographic imaging of estrogen receptor-positive breast tumours.

11. A process for the preparation of an iodotamoxifen derivative according to Claim 1 wherein the iodine atom is radioisotopic, said process comprising reacting a compound of formula



20 wherein R^1 and R^2 are as defined in connection with formula (3) and Y represents a 3- or 4- substituent capable of being cleaved from its benzene ring (including within this definition a non-radioisotopic iodine atom), with a reagent capable of effecting such cleavage and with a source of radioisotopic iodine.


12. A process according to Claim 11 wherein Y is chloro, bromo or iodo.

25 13. A process according to Claim 11 asor 12 wherein the cleavage-effecting reagent is an alkyllithium, the source of radioisotopic iodine is radioisotopic molecular iodine and the reaction is carried out in inert atmosphere.

14. A process according to Claim 11 wherein Y is non-radioisotopic iodo, the cleavage-effecting reagent is a copper salt and the source of radioisotopic iodine is radioisotopic sodium iodide.

30 Patentansprüche

1. 3- und 4-Jodtamoxifenderivate, die Verbindungen der Formel (3) sind



45 worin der Jodsubstituent in der 3- oder 4-Stellung vorliegt und R^1 und R^2 , die gleich oder verschieden sein können, C_1 - C_3 Alkylgruppen darstellen oder R^1 ein Wasserstoffatom und R^2 eine C_1 - C_3 Alkylgruppe darstellt oder R^1 und R^2 zusammen mit dem Stickstoffatom, an das sie gebunden sind, eine gesättigte heterozyklische Gruppe darstellen, sowie ihre pharmazeutisch verträglichen Säureadditionssalze.

50 2. Jodtamoxifenderivate gemäß Anspruch 1, dadurch gekennzeichnet, daß R^1 und R^2 Methylgruppen darstellen oder R^1 und R^2 zusammen mit dem Stickstoffatom eine Pyrrolidinogruppe bedeuten.

3. Jodtamoxifenderivate nach Anspruch 2, dadurch gekennzeichnet, daß der Jodsubstituent sich in 4-Stellung befindet.

55 4. Jodtamoxifenderivate nach Anspruch 1, 2 oder 3, dadurch gekennzeichnet, daß das Jodatome kein Radioisotop ist.

5. Jodtamoxifenderivate nach Anspruch 1, 2, 3 oder 4 zur Verwendung bei der Behandlung von Östrogenrezeptor-positivem Brustkrebs.

6. Jodtamoxifenderivate nach Anspruch 1, 2, 3 oder 4 zur Verwendung bei der Herstellung eines Medikaments zur Behandlung von Östrogenrezeptor-positivem Brustkrebs.


60 7. Pharmazeutische Zusammensetzung enthaltend ein Jodtamoxifenderivat nach Anspruch 1, 2, 3 oder 4 in Verbindung mit einem pharmazeutisch wirksamen Verdünnungsmittel, Träger oder Exzipienten.

8. Jodtamoxifenderivate nach Anspruch 1, 2 oder 3, dadurch gekennzeichnet, daß das Jodatome ^{125}I enthält.

65 9. Radioisotope Jodtamoxifenderivate nach Anspruch 1, 2, 3 oder 8 zur Verwendung bei der Herstellung eines Medikaments zur Behandlung von Östrogenrezeptor-positivem Brustkrebs.

10. Radioisotope Jodtamoxifenderivate nach Anspruch 1, 2 oder 3, worin das Jodatom ^{123}J oder ^{131}J umfaßt, zur Verwendung bei der Herstellung einer Formulierung für die photographische Gammastrahlenabbildung von Östrogenrezeptor-positiven Brusttumoren.

11. Verfahren zur Herstellung eines Jodtamoxifenderivats nach Anspruch 1, worin das Jodatom ein Radioisotop ist, dadurch gekennzeichnet, daß man eine Verbindung der Formel



20 worin R^1 und R^2 die in Zusammenhang mit Formel (3) angegebenen Bedeutungen besitzen und Y einen 3- oder 4-Substituenten bedeutet, der zur Abspaltung von seinem Benzolring befähigt ist (eingeschlossen in diese Definition ist ein nicht-radioaktives Jodatom) mit einem Reagens, das eine solche Abspaltung bewirken kann und mit einer Quelle für radioaktives Jod umsetzt.


22. Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß Y Chlor, Brom oder Jod ist.

23. Verfahren nach Anspruch 11 oder 12, dadurch gekennzeichnet, daß das die Spaltung bewirkende Reagens ein Alkylolithium und die Quelle für Jodradioisotop radioaktives molekulares Jod ist und die Reaktion in einer inerten Atmosphäre durchgeführt wird.

24. Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß Y ein nicht radioaktives Jod bedeutet, das die Spaltung bewirkende Reagens ein Kupfersalz und die Quelle für radioaktives Jod radioisotopes Natriumjodid ist.

Revendications

1. Dérivés de 3- et 4-iodotamoxifène qui sont des composés de formule (3)



50 où le substituant iode occupe la position 3 ou 4 et R^1 et R^2 , qui peuvent être identiques ou différents, représentent des radicaux C_1-3 -alcoyle, ou R^1 représente un atome d'hydrogène et R^2 représente un radical C_1-3 -alcoyle, ou R^1 et R^2 , conjointement avec l'atome d'azote auquel ils sont unis, représentent un radical hétérocyclique saturé, et leurs sels d'addition d'acides pharmaceutiquement acceptables.

2. Dérivés d'iodotamoxifène suivant la revendication 1, dans lesquels R^1 et R^2 représentent des radicaux méthyle ou R^1 et R^2 , conjointement avec l'atome d'azote, représentent un radical pyrrolidino.

3. Dérivés d'iodotamoxifène suivant la revendication 2, dans lesquels le substituant iodo occupe la position 4.

4. Dérivés d'iodotamoxifène suivant la revendication 1, 2 ou 3, dans lesquels l'atome d'iode est non radioisotopique.

5. Dérivés d'iodotamoxifène suivant la revendication 1, 2, 3 ou 4, à utiliser pour le traitement du cancer mammaire à récepteurs œstrogéniques.

6. Dérivés d'iodotamoxifène suivant la revendication 1, 2, 3 ou 4, à utiliser pour la préparation d'un médicament destiné au traitement du cancer mammaire à récepteurs œstrogéniques.


7. Composition pharmaceutique comprenant un dérivé d'iodotamoxifène suivant la revendication 1, 2, 3 ou 4, en association avec un diluant, véhicule ou excipient pharmaceutiquement efficace.

8. Dérivés d'iodotamoxifène suivant la revendication 1, 2 ou 3, dans lesquels l'atome d'iode comprend du ^{125}I .

9. Dérivés d'iodotamoxifène radioisotopiques suivant la revendication 1, 2, 3 ou 8, à utiliser pour la préparation d'un médicament destiné au traitement du cancer mammaire à récepteurs cestrogéniques.

10. Dérivés d'iodotamoxifène radioisotopiques suivant la revendication 1, 2 ou 3, dont l'atome d'iode comprend du ^{123}I ou du ^{131}I à utiliser pour la préparation d'une composition pour former l'image photographique par rayons gamma de tumeurs mammaires à récepteurs cestrogéniques.

11. Procédé de préparation d'un dérivé d'iodotamoxifène suivant la revendication 1, dans lequel l'atome d'iode est radioisotopique, lequel procédé comprend la réaction d'un composé de formule



(5)

où R^1 et R^2 sont tels que définis à propos de la formule (3) et Y représente un substituant en position 3 ou 4 capable d'être séparé de son cycle benzène (en incluant dans cette définition un atome d'iode non radioisotopique) avec un réactif capable d'opérer cette séparation et avec une source d'iode radioisotopique.

12. Procédé suivant la revendication 11, dans lequel Y représente chloro, bromo ou iodo.

13. Procédé suivant la revendication 11 ou 12, dans lequel le réactif opérant la séparation est un alcoyllithium, la source d'iode radioisotopique est de l'iode moléculaire radioisotopique et la réaction est exécutée dans une atmosphère inerte.

14. Procédé suivant la revendication 11, dans lequel Y représente iodo non radioisotopique, le réactif opérant la séparation est un sel de cuivre et la source d'iode radioisotopique est l'iodure de sodium radioisotopique.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☒ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.